Format

Send to

Choose Destination
J Clin Invest. 2010 Feb;120(2):485-97. doi: 10.1172/JCI39397. Epub 2010 Jan 4.

CXCR1 blockade selectively targets human breast cancer stem cells in vitro and in xenografts.

Author information

1
University of Michigan Comprehensive Cancer Center, Department of Internal Medicine/Oncology, Ann Arbor, Michigan 48109-0015, USA. christophe.ginestier@inserm.fr

Abstract

Recent evidence suggests that breast cancer and other solid tumors possess a rare population of cells capable of extensive self-renewal that contribute to metastasis and treatment resistance. We report here the development of a strategy to target these breast cancer stem cells (CSCs) through blockade of the IL-8 receptor CXCR1. CXCR1 blockade using either a CXCR1-specific blocking antibody or repertaxin, a small-molecule CXCR1 inhibitor, selectively depleted the CSC population in 2 human breast cancer cell lines in vitro. Furthermore, this was followed by the induction of massive apoptosis in the bulk tumor population via FASL/FAS signaling. The effects of CXCR1 blockade on CSC viability and on FASL production were mediated by the FAK/AKT/FOXO3A pathway. In addition, repertaxin was able to specifically target the CSC population in human breast cancer xenografts, retarding tumor growth and reducing metastasis. Our data therefore suggest that CXCR1 blockade may provide a novel means of targeting and eliminating breast CSCs.

PMID:
20051626
PMCID:
PMC2810075
DOI:
10.1172/JCI39397
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for American Society for Clinical Investigation Icon for PubMed Central
Loading ...
Support Center